Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

NCT00383994 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Leukemia
Transplantation, Stem Cell
Lymphoid Malignancies
Disorder Related to Transplantation

Interventions

DRUG: GM-CSF
DRUG: Rituximab
BIOLOGICAL: NK Cell Infusion

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]